HIF-2α

• 

ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer

By Sharon Kell|2020-09-21T09:41:33+00:0021 Sep 2020|Uncategorized|

At the European Society of Medical Oncology (ESMO) Virtual Congress [...]

Read More

Comments Off on ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer

• 

ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer

By Sharon Kell|2020-06-02T09:12:44+00:002 Jun 2020|Uncategorized|

Results from a phase II international trial led by researchers [...]

Read More

Comments Off on ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer

• 

Novel HIF-2a inhibitor for patients with advanced kidney cancer

By Sharon Kell|2020-02-24T12:27:02+00:0024 Feb 2020|Drug treatments|

In this interview with Practice Update, Dr Eric Jonasch from [...]

Read More

Comments Off on Novel HIF-2a inhibitor for patients with advanced kidney cancer

• 

ASCO GU 2020: Randomised clinical trial of HIF-2α inhibitor in patients with advanced kidney cancer

By Sharon Kell|2020-02-21T14:08:36+00:0021 Feb 2020|Drug treatments|

A randomised clinical trial of hypoxia inducible factor 2α (HIF-2α) [...]

Read More

Comments Off on ASCO GU 2020: Randomised clinical trial of HIF-2α inhibitor in patients with advanced kidney cancer

• 

VHL disease and HIF-2alpha inhibitor

By Sharon Kell|2020-01-06T11:50:50+00:006 Jan 2020|Drug treatments|

In this video interview, Dr Eric Jonasch from MD Anderson [...]

Read More

Comments Off on VHL disease and HIF-2alpha inhibitor

• 

ESMO 2019: First in human study of HIF-2α inhibitor in patients with advanced kidney cancer

By Sharon Kell|2019-09-30T11:18:58+00:0030 Sep 2019|Drug treatments|

Results from the first in human study of the HIF-2α [...]

Read More

Comments Off on ESMO 2019: First in human study of HIF-2α inhibitor in patients with advanced kidney cancer

• 

HIF-2α inhibitor shows promise in patients with advanced kidney cancer

By Sharon Kell|2019-04-02T15:18:29+00:002 Apr 2019|Drug treatments|

A recent phase I/II clinical trial with PT2977, a hypoxia-inducible [...]

Read More

Comments Off on HIF-2α inhibitor shows promise in patients with advanced kidney cancer

A new class of anti-cancer drug for kidney cancer shows promise

By Sharon Kell|2018-01-04T12:44:16+00:004 Jan 2018|Drug treatments|

Researchers in America are looking at a new class of [...]

Read More

Comments Off on A new class of anti-cancer drug for kidney cancer shows promise

• 

HIF-2α inhibitor shows promise in renal cell carcinoma

By Sharon Kell|2016-06-14T15:24:00+00:0014 Jun 2016|Drug treatments|

The results of a first-in-human phase I clinical trial with [...]

Read More

Comments Off on HIF-2α inhibitor shows promise in renal cell carcinoma